Deutsche Bank’s Cascadian Therapeutics CASC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
$299K Sell
81,083
-244,491
-75% -$1M ﹤0.01% 3838
2017
Q3
$1.33M Sell
325,574
-7,754
-2% -$29.7K ﹤0.01% 2807
2017
Q2
$1.24M Buy
333,328
+39,541
+13% +$157K ﹤0.01% 2876
2017
Q1
$1.22M Buy
293,787
+79,100
+37% +$333K ﹤0.01% 2526
2016
Q4
$925K Buy
214,687
+34,197
+19% +$221K ﹤0.01% 2755
2016
Q3
$1.78M Buy
180,490
+16,585
+10% +$118K ﹤0.01% 2436
2016
Q2
$925K Buy
163,905
+69,011
+73% +$469K ﹤0.01% 2950
2016
Q1
$720K Buy
94,894
+18,309
+24% +$141K ﹤0.01% 3005
2015
Q4
$1.02M Sell
76,585
-15,394
-17% -$265K ﹤0.01% 2862
2015
Q3
$1.51M Buy
91,979
+3,181
+4% +$65.2K ﹤0.01% 2671
2015
Q2
$1.99M Buy
88,798
+7,230
+9% +$114K ﹤0.01% 2459
2015
Q1
$796K Buy
81,568
+52,721
+183% +$517K ﹤0.01% 3015
2014
Q4
$328K Buy
28,847
+28,733
+25,204% +$312K ﹤0.01% 3988
2014
Q3
$1K Sell
114
-51,305
-100% -$784K ﹤0.01% 5830
2014
Q2
$998K Sell
51,419
-7,717
-13% -$136K ﹤0.01% 2945
2014
Q1
$1.06M Sell
59,136
-24,564
-29% -$403K ﹤0.01% 2824
2013
Q4
$883K Sell
83,700
-10,238
-11% -$114K ﹤0.01% 2739
2013
Q3
$1.16M Sell
93,938
-40,836
-30% -$430K ﹤0.01% 2860
2013
Q2
$1.27M Hold
134,774
– – ﹤0.01% 2528

Other funds holding CASC

Deutsche Bank's CASC Position: Q4 2017 in Review

Deutsche Bank reduced its Cascadian Therapeutics (CASC) stake by 75% in Q4 2017, selling an estimated $1M and leaving 81,083 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Deutsche Bank first reported a position in CASC in Q2 2013 and has held it in 19 quarters since. The position peaked at $1.99M in Q2 2015. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

  • Deutsche Bank held 81,083 shares of Cascadian Therapeutics worth $299K as of Q4 2017.
  • Deutsche Bank sold 244,491 Cascadian Therapeutics shares in Q4 2017, an estimated $1M.
  • Cascadian Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q4 2017, its #3838 holding.
  • Deutsche Bank first reported a position in Cascadian Therapeutics in Q2 2013 and has held it in 19 quarters since.
  • Deutsche Bank's Cascadian Therapeutics position peaked at $1.99M in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Cascadian Therapeutics as of Q4 2017.

Based on Deutsche Bank's 13F filing for Q4 2017, filed 14 Feb 2018.